These outcomes surpass those achieved with first-generation anti-obesity medications and lifestyle interventions alone, positioning GLP-1 RAs as highly effective agents in the contemporary pharmacologic management of obesity [54]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.